Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (6): 1100-1103    DOI: 10.12892/ejgo4851.2019
Case Report Previous articles | Next articles
Two cases of recurrent small-cell carcinoma of the uterine cervix treated with amrubicin as salvage chemotherapy
N. Kosaka1, K. Hasegawa1, *(), K. Kiuchi1, S. Ochiai1, E. Motegi1, I. Fukasawa1
1Department of Obstetrics and Gynecology, Dokkyo Medical University, Mibu, Tochigi, Japan
Download:  PDF(692KB)  ( 192 ) Full text   ( 5 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Small-cell carcinoma of the cervix (SCCC) is a rare and aggressive tumor; however, no definitive treatment guidelines for SCCC exist. A review of case series revealed that the most frequently used first-line chemotherapy regimen is combination etoposide and cisplatin, which is also used for small-cell lung cancer (SCLC). For recurrent SCLC, the utility of amrubicin (AMR) has recently been reported. However, optimal second-line chemotherapy for recurrent SCCC has remained unclear. Herein the authors report their experience using AMR as salvage chemotherapy for two patients with recurrent SCCC. AMR resulted in disease stabilization in both patients, with relatively long progression-free survival (PFS) of five and 14 months for platinum-refractory and -sensitive disease, respectively. No severe (grade >3) hematological or non-hematological toxicities were observed. In conclusion, AMR may be as effective and safe for recurrent SCCC as it is for recurrent SCLC. To further evaluate the efficacy and safety of AMR for recurrent SCCC, it is necessary to collect additional case studies or conduct a phase II trial.

Key words:  Small cell carcinomas      Uterine cervix      Amrubicin      Recurrence     
Published:  10 December 2019     
*Corresponding Author(s):  K. HASEGAWA     E-mail:  hasek@dokkyomed.ac.jp

Cite this article: 

N. Kosaka, K. Hasegawa, K. Kiuchi, S. Ochiai, E. Motegi, I. Fukasawa. Two cases of recurrent small-cell carcinoma of the uterine cervix treated with amrubicin as salvage chemotherapy. European Journal of Gynaecological Oncology, 2019, 40(6): 1100-1103.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4851.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I6/1100

[1] T. Uehara, A. Mitsuhashi, M. Shozu. The impact of pre-existing polycystic ovary syndrome on endometrial cancer recurrence[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 668-674.
[2] Špela Smrkolj, Snježana Frković Grazio, Renata Košir Pogačnik. Endocervical adenocarcinoma in situ with ovarian metastasis: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 802-805.
[3] Silvia Ortega, José Angel Mínguez, José Manuel Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Pablo Martí-Cruchaga, Juan Luis Alcázar, Matías Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 523-530.
[4] Z. Zheng, Z.H. Han, Z.T. Li, X.H. Wu. The impact of laparoscopic surgical treatments on oncologic outcome of Stage I uterine leiomyosarcoma[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 977-981.
[5] R. Tinelli, S. Guicciardini, S. Uccella, E. Cicinelli, F. Romano, G. Trojano. A rare case of false positive metastatic nodes detected at PET/CT scan six months after the laparoscopic treatment of a patient with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1039-1040.
[6] F.V. Carvalho Sousa Esteves, L.A. Gomes de Sousa, R.S. Martins, A.L. Ramos Bezerra de Alencar, L. de Deus Sousa, M.C. Cronemberger Guimarães Serzedo, I. Meneses de Carvalho Coelho, S.C. Vieira. Paget’s disease of the breast after nipple-areola sparing mastectomy: case report[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1087-1090.
[7] S. Bertozzi, A. P. Londero, S. Bernardi, C. Cedolini. Applicability of the Notthingham Prognostic Index for predicting the survival of triple-negative invasive breast cancer in a single Italian center[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 787-790.
[8] R. Du, L. Li, S. Ma, X. Tan, S. Zhong, M. Wu. Survival outcomes of Stage IB cervical cancer treated with standard radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 810-814.
[9] F. El-Sharkawy, M. Sittig, C. Nieroda, A. Sardi. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent mucinous cystadenoma of the ovary[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 543-546.
[10] E. Lajtman, M. Mlynček, T. Kapusta, M. Kubalová. The value of gynecological cancer follow-up: a 15-year single institutional experience[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 619-627.
[11] Z. Marchocki, L.A. Norris, F. Abu Saadeh, N. Gleeson. Recurrence of venous thromboembolism in patients with gynaecological malignancies: incidence, risk factors, and impact on survival[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 413-419.
[12] D. Odetto, M.C. Saez, A. Wernicke, J. Saadi, F. Noll, M. Perrotta. Low-risk endometrial carcinoma: is it time to subclassify it?[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 447-451.
[13] Xin Yan, Yu-Nong Gao, Quan Bao, Na An, Min Gao, Hong Zheng. Hepatic resection for recurrent metastatic ovarian carcinoma or peritoneal carcinoma: a retrospective case-control study[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 113-118.
[14] Z. Protrka, A. Dimitrijevic, N. Jovic, T. Kastratovic, J. Djuric, J. Nedovic, S. Zivanovic, A. Vujic, S.M. Drakulic, N. Djonovic, P. Arsenijevic. Expression analysis of the Beclin-1 in premalignant and malignant tissues of the uterine cervix[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 915-920.
[15] A. Abe, M. Nishimura, M. Irahara. "See and treat" LEEP biopsy for cervical intraepithelial neoplasia grade 2/3[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 958-962.
No Suggested Reading articles found!